GE HealthCare has teamed up with Peter MacCallum Cancer Centre to further develop and explore the clinical and research of its total body PET/CT technology.
With a 128cm, ultra-high sensitivity detector, GE HealthCare’s total body PET/CT technology is designed for molecular imaging and cancer patient management.
Under the partnership, Peter MacCallum Cancer Centre will use the total body PET/CT technology designed by GE HealthCare for its research efforts.
Peter MacCallum Cancer Centre PET/CT programme head Michael Hofman said: “Our current PET/CT devices image the body in five to six steps which are then stitched together to create our scans.
“This next-generation technology is being designed with the goal of imaging from head to thighs in a single step, which may create new opportunities for research.
“Combined with deep learning-based capabilities, this technology has the potential to be a major advancement for patients that will support prevention, early detection, and better scanning of advanced cancers.”
GE HealthCare said that its total body PET/CT technology is designed to support research and advance traditional PET by promoting new diagnostic and therapeutic agents.
The technology aims to drive new clinical pathways, support existing molecular imaging and theranostics applications, and enhance healthcare system efficiency.
Its total-body PET/CT technology is designed to support ultra-low dose scans, fast acquisitions, multi-organ dynamic imaging, and imaging of slow decaying tracers.
Also, the advanced imaging system aims to enhance clinical workflows, support routine clinical practice, and improve operational efficiency, said GE HealthCare.
GE HealthCare said the new technology is a scalable solution that enables radiology departments and healthcare facilities to upgrade to a long axial field-of-view PET/CT system.
It supports the addition of new services to address growing demand, optimise clinical capabilities, access to advanced technology, and address evolving community needs.
In addition, the system incorporates intuitive workflow solutions enhanced by artificial intelligence (AI), promoting greater clinical and operational efficiency, said the company.
GE HealthCare molecular imaging and computed tomography president and CEO Jean-Luc Procaccini said: “Innovation requires close collaboration, and we are thrilled to do that with Peter MacCallum Cancer Centre on our total body PET/CT technology.
“Already, the institution’s research has revolutionised cancer imaging and pioneered theranostics.
“Now, we aim to usher in a new era of scientific discovery and research together with a total body PET/CT technology for the future, unlocking its potential to help clinicians further improve patient outcomes.”
